ClinicalTrials.gg
CompletedNCT03875508Updated May 11, 2021Results posted

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Risankizumab and Autoinjector in Psoriasis, sponsored by AbbVie. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
22nd of 30
108 · median 162
Started
2019
with 2 others
Phase 3
17 of 30
none open now
Registered
16th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 22nd largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 3, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.

Read the detailed description

This was a Phase 3 multicenter, single-arm, open-label study that evaluated usability and efficacy of the risankizumab-AI combination product. The study included a 30-day screening period with study visits at Weeks 0, 4, 16, 28, and 40 with a subsequent follow-up telephone call at approximately 20 weeks after the last dose of study drug (Week 48). Study drug dosing consisted of 4 self-administered doses given subcutaneously on Weeks 0, 4, 16, and 28. Dosing on Weeks 4 and 16 was self-administered at home.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Risankizumab
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit
  • Participant meets following disease activity criteria:

    • Stable moderate to severe chronic plaque psoriasis, defined as ≥ 10% body surface area (BSA) psoriasis involvement, static Physician Global Assessment (sPGA) score ≥ 3, and Psoriasis Area Severity Index (PASI) ≥ 12 at Screening and baseline visit
    • Candidate for systemic therapy as assessed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis
  • Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
  • Participant has previous exposure to risankizumab
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28

    Drug: Risankizumab · Device: Autoinjector

Interventions

  • Risankizumab to be injected subcutaneously (SC)

    Also known as: ABBV-066, BI 655066

  • DeviceAutoinjector

    Single dose pre-filled autoinjector containing risankizumab for SC injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Observer Rating of Successful Participant Self-administration

    Successful participant self-administration is defined as successfully completed the sequence of 4 critical steps in the Instructions for Use (IFU) without errors to administer study drug via the autoinjector. The steps are "chose an appropriate injection site"; "removed cap from autoinjector"; "activated the injection"; and "performed a complete injection".

    Time frame: Day 1 and Week 28

  2. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  3. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

    Time frame: At Week 16

  4. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  5. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 at Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

    Time frame: At Week 16

  6. Percentage of Participants Who Had No Potential Hazards as Measured by an Observer

    Potential hazards are measured by an observer on the possible use-related hazards checklist for self-administration with the autoinjector. Hazards include injection at incorrect site; administration delayed because of cap removal difficulties; slip hazard during cap disposal attempt; small component swallowed after incorrect disposal of cap; patient received less medication than intended; needle shield did not deploy and resulted in sharps exposure; and pen not discarded properly and resulted in a biohazard for others.

    Time frame: Day 1 and Week 28

  7. Participant Rating of Acceptability by the Self-Injection Assessment Questionnaire (SIAQ)

    Participants completed the Self-Injection Assessment Questionnaire (SIAQ), an instrument previously validated in those with rheumatoid arthritis, on an electronic patient-report outcome (ePRO) device. The POST module includes four principal causal domains: feelings about injections, self-confidence, pain and reaction during or after the injection, and ease of use, plus two additional domains on satisfaction with self-injection and self-image. Participants rate each item of the SIAQ 20 to 40 minutes following injections, and the ratings are transformed to scores ranging from 0 (worst experience) to 10 (best experience). The domain score is the mean of the item scores included in the domain. Higher domain scores indicate wider acceptability by subjects to use the autoinjector.

    Time frame: Day 1, Week 4, Week 16, Week 28

Other outcomes

  1. Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.

    Time frame: Baseline, Week 4, and Week 16

07

Results

Posted May 11, 2021

Participant flow

Participant flow — Overall Study
MilestoneRisankizumab
Started108
Completed96
Not completed12
Withdrew: Adverse event1
Withdrew: Lost to follow-up8
Withdrew: Lack of efficacy1
Withdrew: Other, not specified2

Outcome measures

PrimaryPercentage of Participants With an Observer Rating of Successful Participant Self-administration

Successful participant self-administration is defined as successfully completed the sequence of 4 critical steps in the Instructions for Use (IFU) without errors to administer study drug via the autoinjector. The steps are "chose an appropriate injection site"; "removed cap from autoinjector"; "activated the injection"; and "performed a complete injection".

Time frame:
Day 1 and Week 28
Reported as:
Number · percentage of participants
Percentage of Participants With an Observer Rating of Successful Participant Self-administration
percentage of participantsRisankizumab
Day 1100
Week 28100
PrimaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16
percentage of participantsRisankizumab
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 1666.7 (57.8 to 75.6)
PrimaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16
percentage of participantsRisankizumab
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 1681.5 (74.2 to 88.8)
PrimaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16
percentage of participantsRisankizumab
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 1646.3 (36.9 to 55.7)
PrimaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 at Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 at Week 16
percentage of participantsRisankizumab
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 at Week 1684.3 (77.4 to 91.1)
PrimaryPercentage of Participants Who Had No Potential Hazards as Measured by an Observer

Potential hazards are measured by an observer on the possible use-related hazards checklist for self-administration with the autoinjector. Hazards include injection at incorrect site; administration delayed because of cap removal difficulties; slip hazard during cap disposal attempt; small component swallowed after incorrect disposal of cap; patient received less medication than intended; needle shield did not deploy and resulted in sharps exposure; and pen not discarded properly and resulted in a biohazard for others.

Time frame:
Day 1 and Week 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Had No Potential Hazards as Measured by an Observer
percentage of participantsRisankizumab
Day 1100
Week 28100
PrimaryParticipant Rating of Acceptability by the Self-Injection Assessment Questionnaire (SIAQ)

Participants completed the Self-Injection Assessment Questionnaire (SIAQ), an instrument previously validated in those with rheumatoid arthritis, on an electronic patient-report outcome (ePRO) device. The POST module includes four principal causal domains: feelings about injections, self-confidence, pain and reaction during or after the injection, and ease of use, plus two additional domains on satisfaction with self-injection and self-image. Participants rate each item of the SIAQ 20 to 40 minutes following injections, and the ratings are transformed to scores ranging from 0 (worst experience) to 10 (best experience). The domain score is the mean of the item scores included in the domain. Higher domain scores indicate wider acceptability by subjects to use the autoinjector.

Time frame:
Day 1, Week 4, Week 16, Week 28
Reported as:
Mean · units on a scale
Participant Rating of Acceptability by the Self-Injection Assessment Questionnaire (SIAQ)
units on a scaleRisankizumab
Feelings about injections- Day 18.358 ± 2.3613
Self-confidence- Day 18.556 ± 2.0646
Satisfaction with self-injection- Day 19.056 ± 1.0321
Injection-site reactions- Day 19.817 ± 0.4469
Ease of use- Day 18.82 ± 1.415
Self-image- Day 19.53 ± 1.261
Feelings about injections- Week 48.478 ± 2.0024
Self-confidence- Week 48.112 ± 2.6313
Satisfaction with self-injection- Week 49.096 ± 1.1572
Injection-site reactions- Week 49.700 ± 0.5710
Ease of use- Week 48.84 ± 1.240
Self-image- Week 49.16 ± 1.964
Feelings about injections- Week 168.750 ± 1.8483
Self-confidence- Week 168.367 ± 2.5921
Satisfaction with self-injection- Week 169.229 ± 1.1517
Injection-site reactions- Week 169.763 ± 0.4576
Ease of use- Week 168.93 ± 1.394
Self-image- Week 169.28 ± 1.678
Feelings about injections- Week 288.675 ± 2.0661
Self-confidence- Week 288.795 ± 2.3034
Satisfaction with self-injection- Week 289.458 ± 1.0500
Injection-site reactions- Week 289.725 ± 0.8911
Ease of use- Week 289.39 ± 0.971
Self-image- Week 289.34 ± 1.614
Other pre-specifiedPercent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.

Time frame:
Baseline, Week 4, and Week 16
Reported as:
Least squares mean · percent change from Baseline
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16
percent change from BaselineRisankizumab
Week 4-61.57 (-66.502 to -56.636)
Week 16-89.33 (-92.915 to -85.750)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 20 weeks after last study drug administration, up to 48 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risankizumab0/108 (0%)6/108 (5.6%)12/108 (11.1%)
Most frequent serious events
Most frequent serious events
EventRisankizumab
ATRIAL FIBRILLATIONCardiac disorders1/108
PYREXIAGeneral disorders1/108
APPENDICITISInfections and infestations1/108
PYELONEPHRITISInfections and infestations1/108
THERMAL BURNInjury, poisoning and procedural complications1/108
LUMBAR SPINAL STENOSISMusculoskeletal and connective tissue disorders1/108
PROSTATITISReproductive system and breast disorders1/108
Most frequent other events
Most frequent other events
EventRisankizumab
NASOPHARYNGITISInfections and infestations8/108
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations6/108

Baseline characteristics

Intent-to-treat (ITT) population: all participants who received at least one dose of study drug

Age, Continuous
Age, Continuous(years)Risankizumab
Mean49.2 ± 14.32
Sex: Female, Male
Sex: Female, Male(Participants)Risankizumab
Female42
Male66
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Risankizumab
White95
Black or African American5
Asian7
American Indian or Alaska Native1
Native Hawaiian or other Pacific Islander0
Other0
Multiple0
Missing0
Prior Use of Systemic Biologic for Psoriasis
Prior Use of Systemic Biologic for Psoriasis(Participants)Risankizumab
060
≥148
Static Physician Global Assessment (sPGA) Score at Baseline
Static Physician Global Assessment (sPGA) Score at Baseline(Participants)Risankizumab
Score of 388
Score of 420
Psoriasis Area and Severity Index (PASI) Score at Baseline
Psoriasis Area and Severity Index (PASI) Score at Baseline(units on a scale)Risankizumab
Mean19.834 ± 7.2424
Body Surface Area (BSA) Psoriasis Involvement at Baseline
Body Surface Area (BSA) Psoriasis Involvement at Baseline(Percentage of body surface area affected)Risankizumab
Mean25.471 ± 17.4671
Duration of Plaque Psoriasis
Duration of Plaque Psoriasis(years)Risankizumab
Mean16.89 ± 13.095
08

Study locations

26 sites
  • Advanced Research Associates /ID# 210634
    Glendale, Arizona 85308, United States
  • Cognitive Clinical Trials /ID# 210770
    Scottsdale, Arizona 85258-4446, United States
  • Burke Pharmaceutical Research /ID# 211386
    Hot Springs, Arkansas 71913-6404, United States
  • Bakersfield Derma & Skin Cance /ID# 210773
    Bakersfield, California 93309, United States
  • Encino Research Center / T. Jo /ID# 211735
    Encino, California 91436, United States
  • Tien Q Nguyen MD, Inc /ID# 210775
    Fountain Valley, California 92708-3701, United States
  • UC Davis Health /ID# 210411
    Sacramento, California 95816, United States
  • Dermatology Physicians of CT /ID# 210637
    Shelton, Connecticut 06484-6211, United States
  • Florida Academic Centers Research /ID# 210337
    Coral Gables, Florida 33134, United States
  • Medallion Clinical Research Institute, LLC /ID# 210329
    Naples, Florida 34102, United States
  • Renstar Medical Research /ID# 210878
    Ocala, Florida 34470, United States
  • Epiphany Dermatology /ID# 211493
    Overland Park, Kansas 66215, United States
  • DermAssociates /ID# 210838
    Rockville, Maryland 20850, United States
  • Great Lakes Research, Inc. /ID# 210192
    Bay City, Michigan 48602, United States
  • Somerset Skin Centre /ID# 211596
    Troy, Michigan 48084, United States
  • Central Dermatology, PC /ID# 210301
    Saint Louis, Missouri 63117, United States
  • AllCutis Research Inc /ID# 211429
    Portsmouth, New Hampshire 03801, United States
  • Medication Management, LLC /ID# 213217
    Greensboro, North Carolina 27408, United States
  • Oregon Medical Res Center PC /ID# 210334
    Portland, Oregon 97223, United States
  • University of Pittsburgh MC /ID# 210839
    Pittsburgh, Pennsylvania 15260, United States
  • Center for Clinical Studies /ID# 211565
    Cypress, Texas 77433, United States
  • Center for Clinical Studies /ID# 210362
    Houston, Texas 77004, United States
  • Suzanne Bruce and Associates /ID# 212210
    Houston, Texas 77056, United States
  • Austin Institute for Clinical Research /ID# 212203
    Pflugerville, Texas 78660, United States
  • Premier Clinical Research /ID# 212209
    Spokane, Washington 99202, United States
  • Froedtert Mem Lutheran Hosp /ID# 210194
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Apr 2020, 10 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 14, 2019
StartActual
Jun 4, 2019
Primary completionActual
Apr 24, 2020
CompletionActual
Aug 25, 2020
Results first posted
May 11, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03875508
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 14, 2019
Start date
Jun 4, 2019
Primary completion
Apr 24, 2020
Completion
Aug 25, 2020
Results posted
May 11, 2021
Last update
May 11, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion